Patent ductus arteriosus (PDA) is a very common condition in immature newborn babies and it
has been associated to morbidity and mortality. Ibuprofen is the drug of choice for PDA
treatment according to the last version of the Cochrane review. Nowadays the best dose
regimen for ibuprofen remains uncertain. The investigators aim to perform a randomized
controlled clinical trial to assess whether echocardiographically guided PDA ibuprofen
treatment versus standard treatment could reduce the number of doses of ibuprofen without
increasing the reopening rate and reducing the side effects associated to this medication.